Conference Coverage

Treatment withdrawal without prior liver biopsy found safe in well-controlled autoimmune hepatitis


 

AT THE LIVER MEETING 2016

– Although current guidance calls for a liver biopsy prior to treatment withdrawal in autoimmune hepatitis (AIH), a retrospective observational analysis conducted by researchers from the Cleveland Clinic offers a different view.

“Maybe not everyone needs a liver biopsy before withdrawing treatment,” Yilien Alonso, MD, an internist at the Cleveland Clinic in Weston, Fla., said in an interview at the annual meeting of the American Association for the Study of Liver Diseases.

Dr. Yilien Alonso stands before her poster Whitney McKnight/Frontline Medical News

Dr. Yilien Alonso

Dr. Alonso and her colleagues found that 1-year outcomes in 34 adults with well-controlled autoimmune hepatitis whose treatment was withdrawn with or without first having a liver biopsy did not have significantly different outcomes. Dr. Alonso presented the findings in a poster presentation.

Both the European Association for Study of the Liver and the AASLD recommend liver biopsy prior to treatment withdrawal in AIH, but the expensive procedure is not without risk of morbidity and mortality. Dr. Alonso and her coinvestigators reviewed the records of 508 AIH patients seen at their institution between January 2001 and April 2015. After excluding the records of patients who’d had juvenile onset of AIH, or who were treated with agents other than corticosteroids and azathioprine, the researchers found 34 adults with similar pretreatment profiles who’d had treatment withdrawal after 2 years of excellent response to treatment, 10 of whom had a liver biopsy prior to treatment withdrawal.

The outcomes at 1 year post treatment withdrawal for all 34 were similar, with no difference in flare rates or reinitiation of treatment. In those who’d had the second liver biopsy, the fibrosis stage was noted at 1 year to have declined in three patients.

“If you have a stable patient population that you are tracking every 3-6 months, we don’t see why you can’t stop the treatment without having to have another invasive procedure,” Dr. Alonso said.

On Twitter @whitneymcknight

Recommended Reading

Hepatitis C infection rates rising in women, young children
HCV Hub
Hepatitis outlook: July 2016
HCV Hub
Elbasvir-grazoprevir works effectively against HCV despite current drug use
HCV Hub
Simple interventions markedly improve hepatitis care
HCV Hub
MBX-8025 yields ‘striking’ efficacy results but new safety signal in primary biliary cholangitis
HCV Hub
Cenicriviroc was well-tolerated but did not outperform placebo across all endpoints
HCV Hub
Therapeutic alternative to liver transplantation could be on horizon in NASH
HCV Hub
VIDEO: Obeticholic acid resulted in reduction of a biomarker for liver fibrosis in PBC
HCV Hub
Study eyed zinc for slowing progression of chronic liver disease
HCV Hub
Lack of health literacy and normal routine implicated in hepatitis B virus treatment nonadherence
HCV Hub